Glaucoma causes progressive damage and death of retinal ganglion cells (RGCs) resulting in blindness. The prevalence of the disease will rise to a projected 3 million Americans by 2020. Our long-term goal is to prevent RGC death in the early stages of glaucoma and preserve vision. The objective of this study is to identify dysfunctional RGCs and the risk of their death, together with the time window of opportunity for their recovery. Our central hypothesis is that RGCs undergo a stage of reversible dysfunction before dying, and that RGC dysfunction is modifiable in a critical period during which RGC electrical activity is responsive to artificial elevation/lowering of the intraocular pressure (IOP). Temporary IOP elevation with be obtained by means of head-down body posture;IOP lowering will be obtained by means of topical treatment. Our study will include 600 subjects with suspicion of glaucoma but with normal vision and visual field that will be longitudinally monitored over 4 years with state-of-the-art pattern electroretinogram (PERG), Spectral-domain Optical Coherence Tomography (SD-OCT), and other clinical measures. PERG losses result from reduced activity of viable RGCs as well as from lack of activity from dead/missing RGCs;OCT losses result from loss of RGC/axon tissue.
Our specific aims will determine the risk of losing substantial RGC/axon tissue over 4 years based on baseline PERG susceptibility to head-down posture (aim1), baseline PERG abnormality (aim 2), and presence/absence of IOP-lowering treatment during follow up. Successful completion of our research will establish the notion that RGC death in glaucoma is preceded by a defined stage of modifiable RGC electrical activity, and that the risk of developing glaucoma can be predicted at baseline based on PERG. The outcome of our research will provide 1) the basis for new provocative tests of RGC functional susceptibility/reversibility using a non-invasive PERG method, 2) information needed for new methods to predict the risk of glaucoma development , 3) the time window for preventing it by timely treatment of high-risk individuals.
In subjects suspected of having glaucoma, the electrical activity of retinal ganglion cells - non- invasively measured by pattern electroretinogram - may be altered or may become temporarily altered when subjects assume a head-down body posture. Altered electrical activity may predict future loss of optic nerve tissue and determine th necessity of intraocular pressure-lowering treatment. Treatment may improve electrical activity and prevent tissue loss. Thus, pattern electroretinogram biomarkers have great relevance for clinical management of the disease.
|Porciatti, Vittorio; Bosse, Brandon; Parekh, Prashant K et al. (2014) Adaptation of the steady-state PERG in early glaucoma. J Glaucoma 23:494-500|
|Guy, John; Feuer, William J; Porciatti, Vittorio et al. (2014) Retinal ganglion cell dysfunction in asymptomatic G11778A: Leber hereditary optic neuropathy. Invest Ophthalmol Vis Sci 55:841-8|
|Lam, Byron L; Feuer, William J; Schiffman, Joyce C et al. (2014) Trial end points and natural history in patients with G11778A Leber hereditary optic neuropathy : preparation for gene therapy clinical trial. JAMA Ophthalmol 132:428-36|
|Banitt, Michael R; Ventura, Lori M; Feuer, William J et al. (2013) Progressive loss of retinal ganglion cell function precedes structural loss by several years in glaucoma suspects. Invest Ophthalmol Vis Sci 54:2346-52|
|Banitt, Michael (2013) The choroid in glaucoma. Curr Opin Ophthalmol 24:125-9|
|Abdelaziz, Amany; Capo, Hilda; Banitt, Michael R et al. (2013) Diplopia after glaucoma drainage device implantation. J AAPOS 17:192-6|
|Ventura, Lori M; Feuer, William J; Porciatti, Vittorio (2012) Progressive loss of retinal ganglion cell function is hindered with IOP-lowering treatment in early glaucoma. Invest Ophthalmol Vis Sci 53:659-63|
|Davis, Janet L; Madow, Brian; Cornett, Jessica et al. (2010) Scale for photographic grading of vitreous haze in uveitis. Am J Ophthalmol 150:637-641.e1|
|Ventura, Lori M; Golubev, Iuri; Feuer, William J et al. (2010) The PERG in diabetic glaucoma suspects with no evidence of retinopathy. J Glaucoma 19:243-7|
|Lam, Byron L; Feuer, William J; Abukhalil, Fawzi et al. (2010) Leber hereditary optic neuropathy gene therapy clinical trial recruitment: year 1. Arch Ophthalmol 128:1129-35|
Showing the most recent 10 out of 25 publications